Scientist II, Cancer Pharmacology, Translational Research

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Scientist II in the Translational Research team, within the Biology Department, you will: As a member of a cross-functional quantitative modeling group, collaborate with team members to develop, validate and refine physiologically-based PK (PBPK), quantitative systems pharmacology (QSP), and semi-mechanistic PK/PD models to support discovery and development-phase projects. Seek and apply innovative modeling approac...